Coherus BioSciences Inc. biosimilars netted $117.5mm in a followon public offering of 5.2mm common shares at $24.25. The company will use the proceeds from the offering to fund sales marketing and manufacturing for CHS1701 pegfilgrastim biosimilar for feb...
↧